EICHOR
● Active Not Recruiting
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Condition: Carcinoma, Pancreatic Ductal · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Sponsor: Pfizer
About this study
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other a…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (27)
| Highlands Oncology Group, PA | Fayetteville, Arkansas, United States | — |
| Highlands Oncology Group, PA | Rogers, Arkansas, United States | — |
| Highlands Oncology Group | Springdale, Arkansas, United States | — |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte, California, United States | — |
| City of Hope Investigational Drug Service (IDS) | Duarte, California, United States | — |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora, Colorado, United States | — |
| University of Colorado Hospital - Anschutz Outpatient Pavilion | Aurora, Colorado, United States | — |
| University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) | Aurora, Colorado, United States | — |
| University of Colorado Hospital | Aurora, Colorado, United States | — |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | — |
| START Midwest | Grand Rapids, Michigan, United States | — |
| Siteman Cancer Center - St Peters | City of Saint Peters, Missouri, United States | — |
+ 15 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.